The activity of two genes may tell doctors who will succeed on tamoxifen therapy for breast cancer and, more importantly, who will fail.That’s the conclusion of a new study that found if high levels of a gene called HOXB13 or low levels of a gene known as IL17BR were expressed, tamoxifen therapy wasn’t successful.The simple gene test, researchers report in the June issue of Cancer Cell, was more than 80 percent accurate in predicting a recurrence of the cancer.
